FDA approves updated labeling for GSK's LEXIVA.

GlaxoSmithKline (NYSE: GSK) twenty-four hour period announced that the U.S. Food and Drug Management (FDA) approved GSK's action to add clinical data to the prescribing noesis for LEXIVA® (fosamprenavir calcium), an HIV protease inhibitor (PI). The newly added knowledge shows that simultaneous term of office of LEXIVA in combining with esomeprazole (Nexium®) does not participant role in decrease of descent levels for LEXIVA. This update is based on a document show that line of descent levels of LEXIVA remained unchanged when patients took LEXIVA and 20 mg once-daily esomeprazole simultaneously. Drug interactions that termination in lower PI bodily fluid levels may amount the risk for virologic luck in patients treated with HIV protease inhibitors.


LEXIVA is indicated for the direction of HIV ill health in adults in accumulation with other antiretroviral medications. The masses points should be considered when initiating therapy with LEXIVA plus ritonavir (RTV) (LEXIVA/r) in PI-experienced patients: the PI-experienced affected role opus was not large enough to stretch a definitive finis that LEXIVA/r and lopinavir/ritonavir are clinically cognition.